Please ensure Javascript is enabled for purposes of website accessibility

Instant Analysis: Allergan Launches $10B Share Buyback Program

By Eric Volkman - May 11, 2016 at 9:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The initiative will launch once the big pile of cash from the Teva deal comes rolling in.

What happened?

Allergan (AGN) is preparing to spend a lot of money buying back its own stock. The company announced, concurrent with its Q1 results, that its board has authorized a share repurchase program worth up to $10 billion.

SOURCE: ALLERGAN

Much of that will be spent within months. According to Allergan's press release on the matter, it expects to shell out $4 billion to $5 billion in the four to six months following launch.

Exactly when the program will begin hasn't yet been determined. Allergan said this is dependent on the receipt of proceeds from the sale of its Actavis Generics unit to Teva Pharmaceutical Industries. Last July, Allergan and Teva agreed to the nearly $41 billion sale, although its closing has been delayed, apparently because of regulatory concerns. It is expected to be completed next month.

Once the deal does close, the buyback program will kick in, according to Allergan.

Does this matter to shareholders?

The move represents a shift for Allergan. In the press release, it implied that its days as a wheeler and dealer were coming to a close, at least for now. "We believe there is no greater investment than Allergan stock," the company quoted its CEO Brent Saunders as saying. He added that when the Teva deal closes "we will have the ability to pay down debt to maintain our investment grade credit ratings and preserve significant firepower to invest for growth."

That shrinking away from mergers and acquisitions could have much to do with the recently failed tie-up between Ireland-based Allergan and Pfizer. The "inversion" deal would have resulted in a merged company headquartered in the island nation. The U.S. government's new regulations on tax-saving inversion deals, however, effectively put the kibosh on it.

So it seems that for now, share buybacks and debt retirement are how Allergan will spend its dosh. That's certainly not a bad way to simultaneously help support the share price -- which took a battering after Pfizer backed away and has yet to fully recover -- and improve the balance sheet. Both efforts should help boost sentiment on the company's stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.